I-Mab Biopharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT03860038
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

I-Mab Biopharma | I-Mab Biopharma Co. Ltd. | I-Mab Biopharma HongKong Limited | I-Mab Biopharma US Limited